pulmoПульмонологияPULMONOLOGIYA0869-01892541-9617Scientific and Practical Journal “PULMONOLOGIYA” LLC10.18093/0869-0189-2013-0-6-119-122pulmo-323Research ArticleЗАМЕТКИ ИЗ ПРАКТИКИPRACTICAL NOTESПрактические возможности ПЭТ / КТ в оценке активности и распространенности саркоидозаReal-life PET / CT abilities to assess activity and extension of sarcoidosisЗайцевА. А.ZaytsevA. A.

д. м. н., начальник пульмонологического отделения 

105094, Москва, пл. Госпитальная, 3. Тел.: (499) 263-10-47.

a-zaicev@yandex.ruАнтипушинаД. Н.AntipushinaD. N.

ст. ординатор пульмонологического отделения 

105094, Москва, пл. Госпитальная, 3. Тел.: (499) 263-56-20.

antipushina@mail.ruСивокозовИ. В.SivokozovI. V.

ст. научный сотрудник 

107564, Москва, Яузская аллея, 2. Тел.: (499) 263-10-47.

grand63@yandex.ruФГКУ "Главный военный клинический госпиталь имени академика Н.Н.Бурденко" МО РФRussian FederationФГБУ "Центральный НИИ туберкулеза" РАМНRussian Federation20132812201306119122Copyright © Зайцев А.А., Антипушина Д.Н., Сивокозов И.В., 20132013Зайцев А.А., Антипушина Д.Н., Сивокозов И.В.Zaytsev A.A., Antipushina D.N., Sivokozov I.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.pulmonology.ru/pulm/article/view/323

Практические возможности ПЭТ / КТ в оценке активности и распространенности саркоидоза.

Real-life PET / CT abilities to assess activity and extension of sarcoidosis.

саркоидозпозитронно-эмиссионная томографиякомпьютерная томографияsarcoidosispositron emission tomographycomputed tomographyReferencesЧучалин А.Г., Визель А.А., Амиров Н.Б. (ред.). Саркоидоз. Учеб.-метод. пособие. Казань: Медицина, 2010.Чучалин А.Г., Визель А.А., Амиров Н.Б. (ред.). Саркоидоз. Учеб.-метод. пособие. Казань: Медицина, 2010.Wells A., Hirani N., et al. Interstitial lung disease guideline: the British and the Irish Thoracic Society Thoracic Society of Australia and New Zealand Thoracic Society in collaboration with the Thoracic Society of Australia and Disease Guideline Group, a subgroup of the British Thoracic Society Standards. Thorax 2008; 63; 1–58.Wells A., Hirani N., et al. Interstitial lung disease guideline: the British and the Irish Thoracic Society Thoracic Society of Australia and New Zealand Thoracic Society in collaboration with the Thoracic Society of Australia and Disease Guideline Group, a subgroup of the British Thoracic Society Standards. Thorax 2008; 63; 1–58.Soussan M., Augier A., Brillet P. et al. Functional Imaging in Extrapulmonary Sarcoidosis: FDG-PET/CT and MR Features. Clin. Nucl. Med. 2013. Aviable at: http://journals.lww.com/nuclearmed/Abstract/publishahead/Functional-Imaging-in-Extrapulmonary-Sarcoidosis-.99737.aspxSoussan M., Augier A., Brillet P. et al. Functional Imaging in Extrapulmonary Sarcoidosis: FDG-PET/CT and MR Features. Clin. Nucl. Med. 2013. Aviable at: http://journals.lww.com/nuclearmed/Abstract/publishahead/Functional-Imaging-in-Extrapulmonary-Sarcoidosis-.99737.aspxSkali H., Schulman A., Dorbala S. 18F-FDG PET/CT for the assessment of myocardial sarcoidosis. Curr. Cardiol. Rep. 2013; 15 (4): 352.Skali H., Schulman A., Dorbala S. 18F-FDG PET/CT for the assessment of myocardial sarcoidosis. Curr. Cardiol. Rep. 2013; 15 (4): 352.Ng D., Jacobs M., Mantil J. Combined C-11 methionine and F-18 FDG PET imaging in a case of neurosarcoidosis. Clin. Nucl. Med. 2006; 31 (7): 373–375.Ng D., Jacobs M., Mantil J. Combined C-11 methionine and F-18 FDG PET imaging in a case of neurosarcoidosis. Clin. Nucl. Med. 2006; 31 (7): 373–375.Aide N., Benayoun M., Kerrou K. et al. Impact of [18F]-flu-orodeoxyglucose ([18F]-FDG) imaging in sarcoidosis: unsuspected neurosarcoidosis discovered by [18F]-FDG PET and early metabolicresponse to corticosteroid therapy. Br. J. Radiol. 2007; 80 (951): e67–e71.Aide N., Benayoun M., Kerrou K. et al. Impact of [18F]-flu-orodeoxyglucose ([18F]-FDG) imaging in sarcoidosis: unsuspected neurosarcoidosis discovered by [18F]-FDG PET and early metabolicresponse to corticosteroid therapy. Br. J. Radiol. 2007; 80 (951): e67–e71.Inoue K., Goto R., Shimomura H., Fukuda H. FDG-PET/CT of sarcoidosis and sarcoid reactions following antineoplastic treatment. Springerplus 2013; 2 (1): 113.Inoue K., Goto R., Shimomura H., Fukuda H. FDG-PET/CT of sarcoidosis and sarcoid reactions following antineoplastic treatment. Springerplus 2013; 2 (1): 113.Videnovic7Ivanov J., Vucinic7Mihailovic V., Artiko V. et al. Responsiveness of FDG PET/CT to treatment of patients with active chronic sarcoidosis. Clin. Nucl. Med. 2013; 38 (7): 516–521.Videnovic7Ivanov J., Vucinic7Mihailovic V., Artiko V. et al. Responsiveness of FDG PET/CT to treatment of patients with active chronic sarcoidosis. Clin. Nucl. Med. 2013; 38 (7): 516–521.Imperiale A., Riehm S., Braun J. Interest of [18F]FDG PET/CT for treatment efficacy assessment in aggressive phenotype of sarcoidosis with special emphasis on sinonasal involvement. Quart. J. Nucl. Med. Mol. Imag. 2013; 57 (2): 177–186.Imperiale A., Riehm S., Braun J. Interest of [18F]FDG PET/CT for treatment efficacy assessment in aggressive phenotype of sarcoidosis with special emphasis on sinonasal involvement. Quart. J. Nucl. Med. Mol. Imag. 2013; 57 (2): 177–186.Coker R. Guidelines for the use of corticosteroids in the treatment of pulmonary sarcoidosis. Drugs 2007; 67 (8): 1139–1147.Coker R. Guidelines for the use of corticosteroids in the treatment of pulmonary sarcoidosis. Drugs 2007; 67 (8): 1139–1147.Ambrosini V., Zompatori M., Fasano L. et al. 18F-FDG PET/CT for the assessment of disease extension and activity in patients with sarcoidosis: Results of a Preliminary Prospective Study. Clin. Nucl. Med. 2013; 38 (4): e171–e177.Ambrosini V., Zompatori M., Fasano L. et al. 18F-FDG PET/CT for the assessment of disease extension and activity in patients with sarcoidosis: Results of a Preliminary Prospective Study. Clin. Nucl. Med. 2013; 38 (4): e171–e177.

The authors declare that there are no conflicts of interest present.